

SeaBeLife Biotech
Primary tabs
About your organization / profile
SeaBeLife pioneers a revolutionary therapeutic paradigm aimed at halving the medical burden, including mortality rates, of severe pathologies lacking effective treatments. Our strategy focuses on developing First-In-Class small Drugs, rooted in a proprietary platform technology comprising small molecules that halt cellular death and forestall organ failure. With a robust pipeline boasting 150 patented molecules exclusively licensed to SeaBeLife, our innovative approach targets critical medical needs. Currently, we are advancing two assets through preclinical development: SBL01, designed to address life-threatening Orphan and Acute Liver Injuries / Failures (ALI/ALF), and SBL03, aiming to preserve vision in Dry-AMD patients, a leading cause of blindness globally among the elderly. These initiatives promise to transform patient outcomes, addressing significant social, economic, and healthcare challenges.
Network (0)
There are no organizations in the network.
Recent activities

SeaBeLife Biotech has taken its fundraising offline.

The dataroom has been updated.

The pitchdeck document has been updated in the dataroom.

SeaBeLife Biotech has updated its fundraising.

SeaBeLife Biotech has published fundraising documents.

Morgane Rousselot has joined SeaBeLife Biotech.